Medivation Inc (MDVN)

MDVN (NASDAQ:Drugs) EQUITY
$81.44
pos +0.02
+0.02%
Today's Range: 81.43 - 81.48 | MDVN Avg Daily Volume: 4,259,000
Last Update: 09/27/16 - 4:14 PM EDT
Volume: 7,203,016
YTD Performance: 68.47%
Open: $81.44
Previous Close: $81.42
52 Week Range: $26.41 - $63.35
Oustanding Shares: 165,928,674
Market Cap: 13,513,231,211
6-Month Chart
TheStreet Ratings Grade for MDVN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 2 3 9 9
Moderate Buy 0 0 0 0
Hold 11 11 4 4
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.69 2.57 1.62 1.62
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -79.07
Price Earnings Comparisons:
MDVN Sector Avg. S&P 500
-79.07 54.10 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
43.86% 95.58% 173.52%
GROWTH 12 Mo 3 Yr CAGR
Revenue 32.80 4.20 0.72
Net Income -11.50 -6.90 0.00
EPS -14.00 -6.50 0.00
Earnings for MDVN:
EBITDA 0.41B
Revenue 0.94B
Average Earnings Estimates

Earnings Estimates data is not available for MDVN.

Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
By

Bret Jensen

 | Apr 5, 2017 | 11:30 AM EDT
Las Vegas Sands and Flexion are in, and the autos are out.
By

Bret Jensen

 | Mar 26, 2017 | 2:00 PM EDT
Answering questions from the Biotech Mailbag on FLXN and SGYP.
By

Bret Jensen

 | Mar 24, 2017 | 11:30 AM EDT
Answering questions from the Biotech Mailbag on FLXN and SGYP.
RMPIA
By

Bret Jensen

 | Feb 15, 2017 | 11:30 AM EST
M&A activity is in a serious upswing, and here are some names to watch.
RMPIA
By

Robert Lang

 | Oct 3, 2016 | 11:00 AM EDT
Despite markets at record highs, companies are satisfying their appetites to grow and find value by buying others.
RMPIA
By

Anders Keitz

 | Aug 24, 2016 | 5:27 PM EDT
Pfizer's second acquisition this week could add risk. Some retailers attract portfolio managers.
By

James "Rev Shark" DePorre

 | Aug 22, 2016 | 4:21 PM EDT
Stocks travel a good distance just to end up nowhere.
By

Bret Jensen

 | Aug 22, 2016 | 4:16 PM EDT
It was nice to fill in for Doug Kass on what was a very uneventful Monday to begin the week. The market traded in an extremely narrow range for the day, and outside the strength in biotech and the weakness in oil after a nice recent rally there really wasn't much of note that happened today. Still, there were some good conversations on the Daily Dairy despite the directionless market.
By

Bret Jensen

 | Aug 22, 2016 | 2:51 PM EDT
Markets continue to trade in a very narrow range and remain largely directionless.
RMPIA
By

Jim Cramer

 | Aug 22, 2016 | 1:36 PM EDT
That's the hot spot in M&A right now.
this chart is showing great bullish...
Now that AAPL has violated the shorter term support, these are the two areas I have to con...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.